Suzanne Grimm, MD
Psychiatry · Wisconsin Rapids, WINPI 1245345230
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 94.0% of the total across 202 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 21 manufacturers, the largest accounting for just 14.5% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $1,470 and has fallen 58.6% since, to $609 in 2025. Among psychiatry clinicians in WI with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 202 payments — averaging $16.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alkermes, Inc.$472
- Vanda Pharmaceuticals Inc.$412
- Otsuka America Pharmaceutical, Inc.$399
- Lundbeck LLC$395
- AbbVie$310
- Teva Pharmaceuticals USA, Inc.$210
- plus $1K from 15 others
What the payments were for
- Food & beverage$3,06594%
- Education$1956%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alkermes, Inc. | 22 | $472 |
| Vanda Pharmaceuticals Inc. | 27 | $412 |
| Otsuka America Pharmaceutical, Inc. | 21 | $399 |
| Lundbeck LLC | 41 | $395 |
| AbbVie(2 entities) | 17 | $310 |
| Teva Pharmaceuticals USA, Inc. | 6 | $210 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 5 | $123 |
| Takeda Pharmaceuticals U.S.A., Inc. | 10 | $117 |
| Axsome Therapeutics, Inc. | 6 | $117 |
| Johnson & Johnson | 11 | $114 |
| E.r. Squibb & Sons, L.L.C. | 5 | $101 |
| Shire North American Group Inc | 6 | $95 |
| Neurocrine Biosciences, Inc. | 4 | $72 |
| Vertical Pharmaceuticals, LLC | 3 | $54 |
| Sunovion Pharmaceuticals Inc. | 5 | $53 |
| Neos Therapeutics, LP | 2 | $52 |
| Indivior Inc. | 3 | $50 |
| Jazz Pharmaceuticals Inc. | 3 | $38 |
| Bausch Health US, LLC | 2 | $34 |
| Adlon Therapeutics L.p. | 2 | $27 |
| Acadia Pharmaceuticals Inc | 1 | $17 |
How this compares
$3,260 in reported general payments places this provider in the 90th percentile of 543 psychiatry providers in Wisconsin.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 53 | $429,111 |
| Invega TrinzaPaliperidone Palmitate | 38 | $343,939 |
| Abilify MaintenaAripiprazole | 99 | $277,859 |
| AristadaAripiprazole Lauroxil | 64 | $183,080 |
| Invega SustennaPaliperidone Palmitate | 57 | $169,150 |
| Abilify AsimtufiiAripiprazole | 14 | $81,153 |
| Risperdal ConstaRisperidone Microspheres | 29 | $71,469 |
| VraylarCariprazine Hcl | 49 | $70,940 |
| PerserisRisperidone | 17 | $44,816 |
| Clozapine | 369 | $43,659 |
| VyvanseLisdexamfetamine Dimesylate | 70 | $27,098 |
| RexultiBrexpiprazole | 19 | $23,854 |
| BelsomraSuvorexant | 53 | $23,492 |
| LybalviOlanzapine/Samidorphan Malate | 12 | $19,024 |
| TrintellixVortioxetine Hydrobromide | 39 | $18,826 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonInvega Trinza, Invega Sustenna, Risperdal Consta | $114 | $584,559124 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $72 | $429,11153 claims |
| Otsuka America Pharmaceutical, Inc.Abilify Maintena, Abilify Asimtufii, Rexulti | $399 | $382,866132 claims |
| Alkermes, Inc.Aristada, Lybalvi | $472 | $202,10476 claims |
| AbbVieVraylar | $310 | $70,94049 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Vyvanse, Trintellix | $117 | $45,924109 claims |
| Indivior Inc.Perseris | $50 | $44,81617 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 543 psychiatry providers in Wisconsin.
Other psychiatry in Wisconsin Rapids
- Scott WienerGreenfield$1.4M
- Joseph BergsRacine$346K
- Royle EenigenburgJuneau$344K
- Thomas IlicMilwaukee$324K
- Jay WinstonMilwaukee$238K
- Joseph BurgarinoMilwaukee$111K
- Sobia Kirmani MoeMadison$104K
- Jacob BehrensMilwaukee$94K
- Ned KalinMadison$48K
- Kenneth HerrmannMadison$42K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.